Precision reacquires rights to allogeneic CAR-Ts from Servier EMA starts review of GSK and Vir's COVID-19 antibody therapy Rapha Capital Management launches $100M life science VC fund with an eye on early science Sponsored: MyData-TRUST is becoming the undisputed world leader in Data Protection for Health Research AI drug prospector Recursion bumps IPO up (again) to $374M Regenerative medicine biotech Surrozen aims for the Nasdaq in $212M SPAC deal The dogtor is in: Study finds dogs can sniff out COVID-19 with 96% accuracy Scientists make long-lasting but controversial human-monkey embryos for medical research Fierce Pharma Asia—Sanofi's €400M vaccine site; BeiGene-Novartis' PD-1 data; India's remdesivir export ban Chutes & Ladders—Lilly, bidding adieu to Shah, lines up Apple exec as CDO Featured Story | By Nick Paul Taylor Precision BioSciences has reacquired the global rights to its allogeneic CAR-T programs. The deal with Servier gives Precision control of assets including a clinical-phase CD19 candidate that it sold off back in 2016 for $105 million. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor The European Medicines Agency (EMA) has begun reviewing GlaxoSmithKline and Vir Biotechnology’s anti-SARS-CoV-2 antibody. The EMA is assessing the candidate in COVID-19 patients who do not require oxygen supplementation and are at high risk of disease progression. read more By Ben Adams Life science venture capital firm Rapha Capital Management has launched its first managed venture capital fund with a target raise of $100M and “solely focused” on investment in early-stage life science companies. read more Sponsored By: MyData-TRUST 34.4% of worldwide data breaches come from the healthcare sector. Data Protection is no longer just a compliance issue, but a strategic topic. MyData-TRUST was created to support the sector. read more By Amirah Al Idrus Recursion Pharmaceuticals ramped up its IPO target from $100 million to $306 million earlier this week, but the artificial intelligence biotech is scratching that plan. Now, it’s aiming to raise $374 million in its Nasdaq debut by adding 4 million more shares to the offering. read more By Amirah Al Idrus After banking two $50 million venture rounds about a year apart, Surrozen is ready to hit Wall Street. The company plans to go public via SPAC in a deal worth up to $212 million. If all goes to plan, the deal will close in the third quarter and the combined company will receive $92 million from the SPAC, as well as $120 million through a private round. It will list on the Nasdaq under the ticker “SRZN.” read more By Andrea Park A new study led by researchers from the University of Pennsylvania found that mass COVID-19 screening could be solved by a quick sniff from a dog—a dognostic test, if you will. read more By Angus Liu Scientists from the Salk Institute and China’s Kunming University of Science and Technology have created chimeric embryos by injecting human stem cells into monkey embryos. The approach could boost research into early human development, as well as drug discovery, the team said, but it also raised ethical questions. read more By Angus Liu Sanofi laid out plans for a €400M vaccine site in Singapore. BeiGene is eyeing global filings for its Novartis-partnered PD-1 inhibitor after survival data in previously treated non-small cell lung cancer. India banned exports of Gilead's remdesivir as local demand surges. And more. read more By Fraiser Kansteiner GSK's vaccine research lead is hitting the exit to run R&D at microbiome company Viome. Eli Lilly tapped an apple exec as its new CDO. And Gilead's oncology head is flying the nest for a post at biotech investor MPM. read more | | Clinical trials are more complex than ever, and you need a central laboratory who can keep pace with your evolving needs. LabConnect is the industry leader when it comes to innovative support services for today’s analytically and logistically complex advanced therapy trials. Contact us today. |
Resources Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: PerkinElmer Informatics Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes. Sponsored By: OCT Clinical Find out why more than 400 clinical trials annually are initiated in Russia by US and EU pharma in the free annual report by OCT Clinical. Sponsored by: PulsePoint Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Pharma PR & Communications Virtual Summit April 20–22, 2021 | Virtual Event Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 12 p.m. EST / 9:00 a.m. PST Medical Affairs Strategic Summit (MASS) Virtual May 5-7, 2021 | Virtual Event TMF Virtual Summit May 18-20, 2021 | Virtual Event Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST | 